News

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
A new COVID variant, NB.1.8.1, was detected in Washington. These are the symptoms to watch for and recommended vaccinations.
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.
A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...
The vaccine is not a replacement for the current Moderna COVID-19 vaccine. The lower-dose vaccine is intended to be a second option. mNexspike is approved for use in individuals who have been ...